ACG: Fewer Overt Hepatic Encephalopathy Episodes Seen With Rifaximin

Follow Drugslib on

Medically reviewed by Judith Stewart, BPharm. Last updated on Oct 28, 2024.

By Elana Gotkine HealthDay Reporter

MONDAY, Oct. 28, 2024 -- For patients with a history of overt hepatic encephalopathy (OHE), rifaximin monotherapy (MT) results in significantly fewer OHE episodes than lactulose (LAC) MT, according to a study presented at the annual meeting of the American College of Gastroenterology, held from Oct. 25 to 30 in Philadelphia.

Jasmohan S. Bajaj, M.D., from Virginia Commonwealth University in Richmond, and colleagues examined the efficacy/safety of LAC MT versus rifaximin MT using data from two randomized trials of adults with cirrhosis and a history of OHE during the previous six months. The analyses included only patients treated with rifaximin 550 mg twice daily (no LAC) or LAC (titrated to two to three soft stools/day; 125 and 145 patients, respectively).

The researchers found that the percentage of patients with an OHE episode was significantly smaller for those treated with rifaximin MT versus LAC MT (23.2 versus 49.0 percent). During six months of treatment, rifaximin MT reduced the risk for a breakthrough OHE episode by 60 percent versus LAC MT, with a number needed to treat of four. The mortality rate was lower for rifaximin MT versus LAC MT (1.6 versus 4.8 percent), with a number needed to treat of 19 (hazard ratio, 0.048). Mortality was reported for 1.6 and 6.9 percent of patients in the rifaximin and LAC MT groups, respectively, through follow-up. More patients in the LAC versus rifaximin group discontinued early from the study (62.1 versus 36.0 percent), most often due to recurrence of HE.

"Rifaximin MT may be an appropriate management approach in select patient populations," the authors write.

Several authors disclosed ties to pharmaceutical companies, including Salix Pharmaceuticals, which manufactures rifaximin.

Abstract

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2024-10-29 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords